Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.
馬薩諸塞州弗雷明翰/ACCESSWIRE/2023年9月5日/Xenetic Biosciences，Inc.(納斯達克股票代碼：XBIO)(以下簡稱“Xenetic”或“公司”)是一家專注於推進創新的免疫腫瘤學技術以解決癌症難治問題的生物製藥公司，今天宣佈，Xenetic首席執行官傑弗裡·艾森伯格將出席H.C.Wainwright 25這是一年一度的全球投資大會將於2023年9月11日至13日在紐約舉行。
In addition to the presentation, management will be available to participate in in-person and virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
除了介紹外，管理層還將與登記參加會議的合格投資者群體成員進行面對面和虛擬的一對一會議。有關大會的更多資訊，請訪問大會網站。
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 11 at 7:00 AM ET for those registered for the event and will be available on the IR Calendar page in the Investors section of the Company's website (). The webcast replay will be archived for 90 days following the event.
9月11日(星期一)美國東部時間上午7：00起，已登記參加活動的人員可通過網路直播觀看演示文稿的視頻，並可在公司網站()投資者部分的IR日曆頁面上觀看。網路直播重播將在活動結束後90天內存檔。
About Xenetic Biosciences
關於遺傳生物科學
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Xenetic Biosciences，Inc.是一家生物製藥公司，專注於推進創新的免疫腫瘤學技術，以解決難以治療的癌症。該公司的DNase平臺旨在通過瞄準與癌症進展和癌症治療耐藥性有關的中性粒細胞外陷阱(Net)來改善包括免疫療法在內的現有治療的結果。Xenetic目前專注於將其全身性DNA ase計劃推向臨床，作為胰腺癌和局部晚期或轉移性實體腫瘤的輔助治療。
For more information, please visit the Company's website at and connect on Twitter, LinkedIn, and Facebook.
欲瞭解更多資訊，請訪問公司網站，並連接Twitter、LinkedIn和Facebook。
Contact:
聯繫方式：
JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com
JTC團隊，有限責任公司
珍妮·託馬斯
(833)475-8247
郵箱：xbio@jtCir.com
SOURCE: Xenetic Biosciences, Inc.
資料來源：Xenetic生物科學公司。